Literature DB >> 22745357

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.

Claudio Rapezzi1, Candida Cristina Quarta, Laura Obici, Federico Perfetto, Simone Longhi, Fabrizio Salvi, Elena Biagini, Massimiliano Lorenzini, Francesco Grigioni, Ornella Leone, Francesco Cappelli, Giovanni Palladini, Paola Rimessi, Alessandra Ferlini, Giorgio Arpesella, Antonio Daniele Pinna, Giampaolo Merlini, Stefano Perlini.   

Abstract

AIMS: Hereditary transthyretin (TTR)-related amyloidosis (ATTR) is mainly considered a neurologic disease. We assessed the phenotypic and genotypic spectra of ATTR in a Caucasian area and evaluated the prevalence, genetic background, and disease profile of cases with an exclusively cardiac phenotype, highlighting possible hints for the differential diagnosis with hypertrophic cardiomyopathy (HCM) and senile systemic amyloidosis (SSA). METHODS AND
RESULTS: In this Italian multicentre study, 186 patients with ATTR were characterized at presentation. Thirty patients with SSA and 30 age-gender-matched HCM patients were used for comparison. Phenotype was classified as exclusively cardiac (n = 31, 17%), exclusively neurologic (n = 46, 25%), and mixed cardiac/neurologic (n = 109, 58%). Among the eight different mutations responsible for an exclusively cardiac phenotype, Ile68Leu was the most frequent. Five patients with an exclusively cardiac phenotype developed mild abnormalities at neurological examination, but no symptoms during a 36-month follow-up (range: 14-50). Exclusively cardiac phenotype was characterized by male gender, age >65 years, heart failure symptoms, symmetric left ventricular (LV) 'hypertrophy', and moderately depressed LV ejection fraction. This profile was similar to SSA, but relatively distinct from HCM. Compared with patients with a mixed phenotype, patients with an exclusively cardiac phenotype showed a more pronounced cardiac involvement on both echocardiogram and electrocardiogram (ECG).
CONCLUSION: A clinically relevant subset of Caucasian ATTR patients present with an exclusively cardiac phenotype, mimicking HCM or SSA. Echocardiographic and ECG findings are useful to differentiate ATTR from HCM but not from SSA. The role of liver transplantation in these patients should be reconsidered.

Entities:  

Mesh:

Year:  2012        PMID: 22745357     DOI: 10.1093/eurheartj/ehs123

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  75 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.

Authors:  Roberta Mussinelli; Francesco Salinaro; Alessio Alogna; Michele Boldrini; Ambra Raimondi; Francesco Musca; Giovanni Palladini; Giampaolo Merlini; Stefano Perlini
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

3.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

4.  Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study.

Authors:  Francesco Cappelli; Raffaele Martone; Giulia Taborchi; Sofia Morini; Simone Bartolini; Paola Angelotti; Silvia Farsetti; Carlo Di Mario; Federico Perfetto
Journal:  Intern Emerg Med       Date:  2018-06-07       Impact factor: 3.397

Review 5.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 6.  Transthyretin Cardiac Amyloidosis.

Authors:  Anit K Mankad; Keyur B Shah
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 7.  Cardiac amyloidosis: the great pretender.

Authors:  Claudio Rapezzi; Massimiliano Lorenzini; Simone Longhi; Agnese Milandri; Christian Gagliardi; Ilaria Bartolomei; Fabrizio Salvi; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

8.  [What gnaws at the heart and gets on the nerves].

Authors:  Arnt V Kristen
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

Review 9.  Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.

Authors:  Giacomo Tini; Pier Filippo Vianello; Chiara Gemelli; Marina Grandis; Marco Canepa
Journal:  J Cardiovasc Transl Res       Date:  2019-01-02       Impact factor: 4.132

10.  18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Authors:  Mi-Ae Park; Robert F Padera; Anthony Belanger; Shipra Dubey; David H Hwang; Vikas Veeranna; Rodney H Falk; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2015-08       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.